Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients

AstraZeneca

Status: Completed

Conditions: COPD

Study type: Observational

Funder types: Industry

Identifiers

NCT01921127

000152

Details and patient eligibility

About

This study is intended to evaluate treatment effectiveness of BFC compared to FSC in COPD patients new to ICS/LABA combination therapy.

Enrollment: 3,000 estimated patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Continuous health plan enrollment for 12 months before and after index Rx, at least one prescription for BFC or FSC during intake period, naive to ICS/LABA therapies in year prior to first prescription claim, COPD diagnosis, aged 40 or over at time of first prescription.

Exclusion criteria

• ICS/LABA combination during pre-index period, patients with a claim for BFC and FSC on the same day, patients diagnosed with cancer, patients with long-term OCS medication use during pre-index period.

Trial design

3,000 participants in 2 patient groups

Symbicort

Description:

BFC patients new to ICS/LABA therapies

Advair

Description:

FSC patients new to ICS/LABA therapies.